ChemGenex Pharmaceuticals Ltd. plunged the most in 16 years in Sydney trading after U.S. regulators said they want to see more clinical test data before reviewing the company’s leukemia drug.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.